EDSA - Edesa Biotech posts positive interim results in EB01 Dermatitis trial

Edesa Biotech (EDSA) announces that the company's drug candidate EB01 has met a key interim study parameter in a mid-stage Allergic Contact Dermatitis ((ACD)) trial.Shares up nearly 4% premarket.The company has now passed the initial inflection point of its Phase2b study and will continue enrolling the final cohort of patients.Edesa reported that interim study data from the first cohort met statistical thresholds as part of an adaptive Phase 2b trial evaluating EB01 as a monotherapy for moderate to severe chronic ACD.The initial cohort analyzed consisted of a population of 46 subjects, of whom 36 completed the study follow-up and were used in the interim analysis.Based on the findings, the DSMB recommended progression to the second cohort of patients.Edesa had entered into a definitive license agreement to acquire additional global rights to a non-steroidal anti-inflammatory technology that forms the basis of the company's EB01 and EB02 drug candidates, in March.

For further details see:

Edesa Biotech posts positive interim results in EB01 Dermatitis trial